Head-to-head evidence
LN-145 vs RP1
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: No discrete molecular target · full Non-Small Cell Lung Cancer pipeline
LN-145
Developed by Iovance Biotherapeutics
NCT03645928 · Phase 2 · terminated
This open-label study gave tumor-infiltrating lymphocyte therapy (lifileucel or LN-145), alone or combined with checkpoint inhibitors, to patients with advanced melanoma, head-and-neck cancer or non-small-cell lung cancer across multiple non-randomized treatment cohorts, with objective response rate as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2030 · NCT04614103 (registry estimate)
RP1
Developed by Replimune, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT03767348 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LN-145's landscape · RP1's landscape